. Editorial. (2017). RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY. Столичная издательская компания.
Chicago Style (17th ed.) Citation. Editorial. RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY. Столичная издательская компания, 2017.
MLA (9th ed.) Citation. Editorial. RIVAROXABAN HAS DEMONSTRATED AN ADVANTAGE OVER ACETYLSALICYLIC ACID IN PREVENTING THE RECURRENCE OF VENOUS THROMBOEMBOLIC EVENTS IN THE EINSTEIN CHOICE STUDY. Столичная издательская компания, 2017.
Warning: These citations may not always be 100% accurate.